1998
Founded
1998
Founded
A peptide company takes shape.
Hybio was established with a singular commitment: develop peptide medicines that protect life and health.
Our Story
Built through science. Expanded through trust.
Since 1998, Hybio has grown from a focused peptide research company into an integrated global platform for peptide and oligonucleotide therapeutics.
2000–2011
R&D Growth
2000–2011
R&D Growth
Research became an industrial capability.
China's first peptide R&D center, GMP-scale production, new drug applications, and a Shenzhen Stock Exchange listing established the foundation for sustained innovation.
2015–2024
Global Expansion
2015–2024
Global Expansion
Quality opened the world.
International regulatory approvals and inspections across the United States, Europe, Brazil, Australia, and Asia accelerated Hybio's global commercial reach.
Today
Current Platform
Today
Current Platform
One platform, from molecule to medicine.
AI-enabled discovery, peptide and oligonucleotide development, API production, finished dosage forms, and CRDMO services now operate as one connected value chain.
